Literature DB >> 3511284

Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.

H W Herr, C M Pinsky, W F Whitmore, P C Sogani, H F Oettgen, M R Melamed.   

Abstract

Intravesical bacillus Calmette-Guerin is effective therapy for multifocal carcinoma in situ of the bladder. The duration of this favorable response and its effect on disease progression are the subject of this report. Between March 1978 and July 1981, 47 patients with diffuse, often symptomatic, carcinoma in situ were treated with intravesical bacillus Calmette-Guerin and followed every 3 to 4 months with cystoendoscopy, biopsy and urine cytology for 3 to 6 years. All patients had had prior or concurrent superficial papillary tumors controlled initially by transurethral resection and fulguration 2 to 3 weeks before bacillus Calmette-Guerin treatment. Of the 47 patients 23 were entered into a randomized study, and received intravesical and percutaneous bacillus Calmette-Guerin. Another 24 patients with carcinoma in situ were treated with intravesical bacillus Calmette-Guerin alone. Bacillus Calmette-Guerin (Pasteur strain) was given intravesically (120 mg. in 50 ml. saline) weekly for 6 weeks. Of the 47 patients 32 (68 per cent) are free of disease (negative urine cytology, cystoendoscopy and biopsy): 15 (65 per cent) after combined bacillus Calmette-Guerin for a median duration of 51 months (range 37 to 75 months) and 17 (71 per cent) after intravesical bacillus Calmette-Guerin alone for a median of 45 months (range 36 to 53 months). Of the 23 patients in the randomized study 4 (17 per cent) have required cystectomy for local progression of disease compared to 17 of 26 controls (65 per cent) who were randomized to transurethral resection and fulguration alone. Cystectomy was performed 3 to 27 months after bacillus Calmette-Guerin treatment and in 3 patients tumor was localized to the prostate gland (no tumor found within the bladder). These data indicate that intravesical bacillus Calmette-Guerin is capable of producing long-term remissions of carcinoma in situ in high risk patients and may prevent or delay progression of disease necessitating cystectomy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511284     DOI: 10.1016/s0022-5347(17)45604-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  21 in total

Review 1.  Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.

Authors:  Elisa Tinazzi; Vincenzo Ficarra; Sara Simeoni; Walter Artibani; Claudio Lunardi
Journal:  Rheumatol Int       Date:  2005-10-12       Impact factor: 2.631

2.  Local BCG therapy of superficial bladder tumours.

Authors:  J Kondás; E Szentgyörgyi; L Szecsö; G Kondér
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

3.  The Nd:YAG laser and methylene blue staining in the diagnosis and treatment of premalignant vesical lesions and carcinoma in situ (CIS).

Authors:  F Gaboardi; R Bordinazzo; L Galli
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

4.  Possible factors affecting response to intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis.

Authors:  M Takashi; S Katsuno; H Yuba; S Ohshima; K Wakai; Y Ohno
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

5.  Bacillus Calmette-Guérin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients.

Authors:  P Conti; M Reale; M Nicolai; R C Barbacane; F C Placido; R Iantorno; R Tenaglia
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

6.  Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.

Authors:  E C de Boer; T M De Reijke; D H Schamhart; P C Vos; K H Kurth
Journal:  Urol Res       Date:  1993

7.  Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).

Authors:  T M de Reijke; P C Vos; E C de Boer; R F Bevers; W H de Muinck Keizer; K H Kurth; D H Schamhart
Journal:  Urol Res       Date:  1993

8.  Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

Authors:  Y Luo; H Yamada; X Chen; A A Ryan; D P Evanoff; J A Triccas; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

9.  The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy.

Authors:  A M Jackson; S Prescott; S J Hawkyard; K James; G Chisholm
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

10.  Total cystectomy after intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer: experience in Japan.

Authors:  M Takashi; A Kondo; Y Nakano; Y Takagi; T Sakata; K Miyake
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.